00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Joicela lumiracoxib regulatory update

Novartis withdrew an MAA in Europe for Joicela lumiracoxib in combination with a companion diagnostic to treat osteoarthritis (OA) of the knee and hip in patients who do not carry the 0102 allele of major...
01:10 , Apr 20, 2011 |  BC Extra  |  Company News

Novartis reports acromegaly data, earnings

Novartis AG (NYSE:NVS; SIX:NOVN) said pasireotide met the primary endpoint of normalization of IGF-1 and growth hormone levels vs. the pharma's Sandostatin LAR octreotide in a Phase III trial to treat acromegaly. Novartis disclosed the...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Linkage Biosciences sales and marketing update

Linkage Biosciences launched three human leukocyte antigen (HLA) typing tests in the U.S. The intermediate resolution HLA-DQ test types the major histocompatibility complex class II DQ locus alpha 1 ( HLA-DQA1 ) and major histocompatibility...
07:00 , Aug 16, 2010 |  BioCentury  |  Strategy

Technology-agnostic diagnostics

When Novartis AG launched its molecular diagnostics unit in late 2008, it said it would pursue partnerships for discovering and developing biomarkers to augment its internal capabilities. The pharma struck its second such collaboration last...
07:00 , Jul 29, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver failure Major histocompatibility complex class II DQ a1 (HLA-DQA1) Genetic studies identified a variant of HLA that could help predict susceptibility to Prexige...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Genome Diagnostics B.V., Qiagen deal

The parties added six additional tests and expanded to 2011 a 2006 deal to develop and commercialize molecular diagnostics to detect genetic variations in the human leukocyte antigen (HLA) complex. Genome Diagnostics will develop the...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease; Crohn's disease; multiple sclerosis (MS); myasthenia gravis; rheumatoid arthritis (RA); selective IgA deficiency; systemic lupus erythematosus (SLE); ulcerative colitis (UC) Major...